Effects of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) administered by intramuscular injection on frequency oscillatory power bands in healthy adults

This single-blind, non-randomised trial (n=15) aims to explore the effects of intramuscularly administered 5-MeO-DMT (3-9 mg) on human brain activity and well-being indicators.

The study involves 15 healthy volunteers who will receive 5-MeO-DMT at doses of 3 mg, 6 mg, and 9 mg, as well as an inactive placebo over four dosing days, spaced two weeks apart.

The primary outcome will assess the acute and post-acute effects of 5-MeO-DMT on frequency oscillatory power bands via magnetoencephalography (MEG).

Secondary outcomes will include assessments of emotional regulation, decentering, suggestibility, social desirability, resilience, interoceptive awareness, satisfaction with life, symptoms of depression, anxiety and stress, mindfulness, self-regulation, spiritual bypassing, somatic symptoms, sleep measures, personality, physical symptoms, occurrence of hallucinogen persisting perception disorder (HPPD), reactivation, adverse psychological effects, resting state cognition, degree of challenge of experience, mystical experience, ego dissolution, acceptance-promoting experience, emotional breakthrough, experiences of love, somatic experiences, and avoidance-promoting experience. The study will also evaluate safety parameters and pharmacokinetics.

The trial, conducted by Swinburne University of Technology in Australia, is expected to commence in September 2023, with a primary focus on safety and efficacy in treating depression.

Topic Depression
Compound 5-MeO-DMT Placebo
Country Australia
Visit trial
Status Not yet recruiting
Results Published No
Start date 01 September 2023
End date 01 January 2025
Phase Phase I
Design Blinded
Type Interventional
Generation First
Participants 15
Sex All
Age 18- 40
Therapy No

Trial Details

This study aims to improve the scientific understanding of the effects of intramuscularly (IM) administered 5-MeO-DMT on human brain activity as well as other indexes of well-being as assessed through psychological, physiological, and biological markers. Finally, we aim to further our understanding of the tolerability and safety profile as well as dose-dependent effects of different doses of 5-MeO-DMT or placebo administered per intramuscular administration and to uncover its phenomenological characteristics.

Trial Number ACTRN12623000884606

Sponsors & Collaborators

Swinburne University of Technology
Swinburne University of Technology, located in Melbourne, Australia, is known for its focus on innovation, industry engagement, and social inclusion.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.